Advertisement

Annals of Surgical Oncology

, Volume 18, Issue 10, pp 2858–2865 | Cite as

The Negative Effect of Triple-Negative Breast Cancer on Outcome after Breast-Conserving Therapy

  • Sandra S. Zaky
  • MaryJo Lund
  • Kelly A. May
  • Karen D. Godette
  • Jonathan J. Beitler
  • Leslie R. Holmes
  • Ruth M. O’Regan
  • Esther S. Yu
  • David S. Yu
  • Jerome C. Landry
Breast Oncology

Abstract

Purpose

To evaluate disease failure patterns and overall survival (OS) of women with triple-negative (TN) breast cancer who underwent breast-conserving therapy (BCT) and to understand the relationship of TN tumors with other prognostic factors.

Patients and Methods

The Surveillance, Epidemiology, and End Results (SEER) registry identified 562 women diagnosed and/or treated with unilateral invasive breast cancer during 2003–2004 at three Emory hospitals. After medical record review, 193 eligible women, with all tumor types, received BCT. Primary endpoints (local, regional, and distant recurrences) and secondary endpoint (OS) were evaluated using chi-square tests and Cox proportional hazards models.

Results

Of the 193 women, 33 (17.1%) had TN tumors and 160 (82.9%) had non-TN tumors. Patient characteristics were similar between the two tumor types; however, tumor grade and use of chemotherapy and hormones differed between the two groups. Median follow-up was 3.4 years; 22 patients had recurrence (12.2%), and 12 died (6.2%). Patients with TN tumors had higher local (12% versus 4% for non-TN) and distant recurrences (15% versus 4% for non-TN) rates (p = 0.01). On multivariate survival analyses, TN status [hazard ratio (HR) 1.8, 95% confidence interval (CI) 1.13–2.93] and African American (AA) race (HR 1.9, 95%CI 1.2–3.07) were independent predictors of inferior OS.

Conclusions

Patients with TN breast cancer showed significant increases in local and distant metastatic recurrence rates after BCT, and TN status and AA race were independent negative predictors of survival. For the future, identification of these high risk features may bring personalized medicine closer to reality.

Keywords

Overall Survival Progesterone Receptor African American African American Patient African American Race 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

M.J.L. received funding from Sindab Endowment, Avon Breast Cancer Grant, and as a Glen Scholar.

Conflicts of interest

There are no disclaimers or conflicts of interest.

References

  1. 1.
    American Cancer Society. Cancer Facts and Figures 2009. Available from URL: http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2009.asp?from=fast. Accessed February 5, 2010.
  2. 2.
    Beadle BM, Woodward WA, Tucker SL, et al. Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys. 2009;73:734–44.PubMedCrossRefGoogle Scholar
  3. 3.
    Lund MJ, Brawley OP, Ward KC, et al. Parity and disparity in first course treatment of invasive breast cancer. Breast Cancer Res Treat. 2008;109:545–57.PubMedCrossRefGoogle Scholar
  4. 4.
    Moran MS, Yang Q, Harris LN, et al. Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer. Cancer. 2008;113:2565–74.PubMedCrossRefGoogle Scholar
  5. 5.
    Pierce L, Fowble B, Solin LJ, et al. Conservative surgery and radiation therapy in black women with early stage breast cancer. Patterns of failure and analysis of outcome. Cancer. 1992;69:2831–41.Google Scholar
  6. 6.
    De Jesus MA, Fujita M, Kim KS, et al. Retrospective analysis of breast cancer among young African American females. Breast Cancer Res Treat. 2003;78:81–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Kroger N, Milde-Langosch K, Riethdorf S, et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res. 2006;12:159–68.PubMedCrossRefGoogle Scholar
  8. 8.
    Wiechmann L, Sampson M, Stempel M, et al. Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol. 2009;16:2705–10.PubMedCrossRefGoogle Scholar
  9. 9.
    Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26:2373–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.PubMedCrossRefGoogle Scholar
  11. 11.
    Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24:5652–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Greene FL, Page DL, Fleming ID, et al. (editors). AJCC cancer staging handbook, 6th edn. New York: Springer-Verlag; 2002.Google Scholar
  13. 13.
    Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.PubMedCrossRefGoogle Scholar
  14. 14.
    Voduc KD, Cheang MC, Tyldesley S. Breast cancer subtypes and the risk of local and regional relapse. JCO. 2010;28:1684–91.CrossRefGoogle Scholar
  15. 15.
    Freedman GM, Anderson PR, Li T, et al. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer. 2009;115:946–51.PubMedCrossRefGoogle Scholar
  16. 16.
    Newman LA, Griffith KA, Jatoi I, et al. Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol. 2006;24:1342–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Eley JW, Hill HA, Chen VW, et al. Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA. 1994;272:947–54.PubMedCrossRefGoogle Scholar
  18. 18.
    Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–502.PubMedCrossRefGoogle Scholar
  19. 19.
    Albain KS, Unger JM, Crowley JJ, et al. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst. 2009;101:984–92.PubMedCrossRefGoogle Scholar
  20. 20.
    Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.PubMedGoogle Scholar
  21. 21.
    Ihemelandu CU, Naab TJ, Mezghebe HM, et al. Treatment and survival outcome for molecular breast cancer subtypes in black women. Ann Surg. 2008;247:463–9.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • Sandra S. Zaky
    • 1
  • MaryJo Lund
    • 2
  • Kelly A. May
    • 3
  • Karen D. Godette
    • 1
  • Jonathan J. Beitler
    • 1
  • Leslie R. Holmes
    • 1
  • Ruth M. O’Regan
    • 3
  • Esther S. Yu
    • 1
  • David S. Yu
    • 1
  • Jerome C. Landry
    • 1
  1. 1.Department of Radiation OncologyEmory University Winship Cancer CenterAtlantaUSA
  2. 2.Departments of Epidemiology and Hematology/Oncology (Joint), Rollins School of Public Health & Emory School of MedicineEmory University Winship Cancer CenterAtlantaUSA
  3. 3.Department of Hematology/Medical OncologyEmory University Winship Cancer CenterAtlantaUSA

Personalised recommendations